WO2025015182A3 - Compositions et procédés de traitement de l'auto-immunité - Google Patents

Compositions et procédés de traitement de l'auto-immunité Download PDF

Info

Publication number
WO2025015182A3
WO2025015182A3 PCT/US2024/037626 US2024037626W WO2025015182A3 WO 2025015182 A3 WO2025015182 A3 WO 2025015182A3 US 2024037626 W US2024037626 W US 2024037626W WO 2025015182 A3 WO2025015182 A3 WO 2025015182A3
Authority
WO
WIPO (PCT)
Prior art keywords
pkg1
methods
subject
protein kinase
upregulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/037626
Other languages
English (en)
Other versions
WO2025015182A2 (fr
Inventor
Timothy NIEWOLD
Ruth FERNANDEZ RUIZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Society for Relief of Ruptured and Crippled
Original Assignee
New York Society for Relief of Ruptured and Crippled
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Society for Relief of Ruptured and Crippled filed Critical New York Society for Relief of Ruptured and Crippled
Publication of WO2025015182A2 publication Critical patent/WO2025015182A2/fr
Publication of WO2025015182A3 publication Critical patent/WO2025015182A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de traitement de maladies auto-immunes telles que le lupus érythémateux disséminé (SLE) chez un sujet par régulation à la hausse de la protéine kinase I dépendante du GMP cyclique (PKG1).
PCT/US2024/037626 2023-07-12 2024-07-11 Compositions et procédés de traitement de l'auto-immunité Pending WO2025015182A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363513260P 2023-07-12 2023-07-12
US63/513,260 2023-07-12

Publications (2)

Publication Number Publication Date
WO2025015182A2 WO2025015182A2 (fr) 2025-01-16
WO2025015182A3 true WO2025015182A3 (fr) 2025-04-03

Family

ID=94216368

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/037626 Pending WO2025015182A2 (fr) 2023-07-12 2024-07-11 Compositions et procédés de traitement de l'auto-immunité

Country Status (1)

Country Link
WO (1) WO2025015182A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160974A1 (en) * 2001-01-09 2002-10-31 Banchereau Jacques F. Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US20180265925A1 (en) * 2015-10-05 2018-09-20 Ucb Biopharma Sprl Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
WO2022064075A1 (fr) * 2020-09-28 2022-03-31 Ermium Therapeutics Dérivés d'isothio-urée cycliques utilisés comme modulateurs du cxcr4

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160974A1 (en) * 2001-01-09 2002-10-31 Banchereau Jacques F. Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US20180265925A1 (en) * 2015-10-05 2018-09-20 Ucb Biopharma Sprl Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
WO2022064075A1 (fr) * 2020-09-28 2022-03-31 Ermium Therapeutics Dérivés d'isothio-urée cycliques utilisés comme modulateurs du cxcr4

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRODERICK KATE E., ZHANG TONG, RANGASWAMI HEMA, ZENG YING, ZHAO XIN, BOSS GERRY R., PILZ RENATE B.: "Guanosine 3′,5′-Cyclic Monophosphate (cGMP)/cGMP-Dependent Protein Kinase Induce Interleukin-6 Transcription in Osteoblasts", MOLECULAR ENDOCRINOLOGY, THE ENDOCRINE SOCIETY, US, vol. 21, no. 5, 1 May 2007 (2007-05-01), US , pages 1148 - 1162, XP009562294, ISSN: 0888-8809, DOI: 10.1210/me.2005-0389 *
GRAY ET AL.: "Activation of conventional protein kinase C (PKC) is critical in the generation of human neutrophil extracellular traps", J INFLAMM (LOND, vol. 10, 2013, pages 12, XP021148353, DOI: 10.1186/1476-9255-10-12 *
ISGRO JOSEPHINE, GUPTA SANJAY, JACEK ELZBIETA, PAVRI TANYA, DUCULAN ROLAND, KIM MIMI, KIROU KYRIAKOS A., SALMON JANE E., PERNIS AL: "Enhanced Rho‐Associated Protein Kinase Activation in Patients With Systemic Lupus Erythematosus", ARTHRITIS & RHEUMATISM, WILEY INTERSCIENCE, US, vol. 65, no. 6, 1 June 2013 (2013-06-01), US , pages 1592 - 1602, XP093301717, ISSN: 0004-3591, DOI: 10.1002/art.37934 *

Also Published As

Publication number Publication date
WO2025015182A2 (fr) 2025-01-16

Similar Documents

Publication Publication Date Title
Bettigole et al. Endoplasmic reticulum stress in immunity
Re et al. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells
Matsumura et al. TRAF6‐NF‐κB pathway is essential for interleukin‐1‐induced TLR2 expression and its functional response to TLR2 ligand in murine hepatocytes
Dantas et al. Mitochondrial uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality control
Strle et al. lnterleukin-10 in the Brain
Tang et al. Soluble egg antigen activates M2 macrophages via the STAT6 and PI3K pathways, and Schistosoma japonicum alternatively activates macrophage polarization to improve the survival rate of septic mice
Sacerdote et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients
Labrosse et al. A RhoGAP protein as a main immune suppressive factor in the Leptopilina boulardi (Hymenoptera, Figitidae)–Drosophila melanogaster interaction
Linossi et al. Suppression of cytokine signaling: the SOCS perspective
McIntosh et al. α-Conotoxin GIC from Conus geographus, a novel peptide antagonist of nicotinic acetylcholine receptors
Choi et al. Human cathelicidin LL‐37 and its derivative IG‐19 regulate interleukin‐32‐induced inflammation
Jin et al. Sodium ferulate prevents amyloid‐beta‐induced neurotoxicity through suppression of p38 MAPK and upregulation of ERK‐1/2 and Akt/protein kinase B in rat hippocampus 1
Buccione et al. Role of interferon regulatory factor 1 in governing T reg depletion, T h1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide
Mun et al. Toll-like receptor 4 mediates tolerance in macrophages stimulated with Toxoplasma gondii-derived heat shock protein 70
Pareek et al. Cdk5: a new player in pain signaling
Inaba et al. Growth arrest and DNA damage‐inducible 34 regulates liver regeneration in hepatic steatosis in mice
Ohashi et al. Protective roles of redox-active protein thioredoxin-1 for severe acute pancreatitis
EA200600618A1 (ru) Применение эффекторов глутаминил- и глутаматциклаз
Yeh et al. Inhibition of NF-κB activation can attenuate ischemia/reperfusion-induced contractility impairment via decreasing cardiomyocytic proinflammatory gene up-regulation and matrix metalloproteinase expression
Gurfinkel et al. Ketamine improves survival in burn injury followed by sepsis in rats
Rau et al. Effects of immunosuppressive and immunostimulative treatment on pancreatic injury and mortality in severe acute experimental pancreatitis
Sano et al. NLRP3 inflammasome is involved in testicular inflammation induced by lipopolysaccharide in mice
Maciel et al. Cardioprotection by the transfer of coronary effluent from ischaemic preconditioned rat hearts: identification of cardioprotective humoral factors
EP2050458A1 (fr) IL24 pour l'induction de la mort cellulaire hyperproliférative ou autoimmune
Harada et al. Hypothermia inhibits translocation of CaM kinase II and PKC‐α, β, γ isoforms and fodrin proteolysis in rat brain synaptosome during ischemia‐reperfusion

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE